ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Onconova Therapeutics and the Leukemia & Lymphoma Society have partnered to push Estybon, Onconova’s myelodysplastic syndrome treatment, toward commercialization. LLS will provide up to $10 million in funding for what the partners call an “approval track” clinical trial in patients with the blood disease. This is the first time the nonprofit is funding a trial of this scale under its Therapy Acceleration Program, a vehicle established in 2007 to support for-profit enterprises that advance leukemia and lymphoma treatments.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter